Table 1.
Demographic and Clinicopathological Characteristics of the Patients, According to Treatment Group.*
| Characteristic | Total (N = 692) |
Weekly Paclitaxel (N = 346) |
Every-3-Wk Paclitaxel (N = 346) |
|---|---|---|---|
| number (percent) | |||
| Age <60 yr | 315 (46) | 156 (45) | 159 (46) |
| Stage of disease | |||
| II | 18 (3) | 8 (2) | 10 (3) |
| III | 464 (67) | 241 (70) | 223 (64) |
| IV | 210 (30) | 97 (28) | 113 (33) |
| Site of origin | |||
| Ovary | 550 (79) | 269 (78) | 281 (81) |
| Fallopian tube | 68 (10) | 36 (10) | 32 (9) |
| Peritoneum | 74 (11) | 41 (12) | 33 (10) |
| Size of residual disease | |||
| Microscopic | 166 (24) | 84 (24) | 82 (24) |
| Gross | 438 (63) | 218 (63) | 220 (64) |
| Not assessed† | 88 (13) | 44 (13) | 44 (13) |
| Histologic features | |||
| Serous | 611 (88) | 302 (87) | 309 (89) |
| Endometrioid | 16 (2) | 8 (2) | 8 (2) |
| Clear cell | 18 (3) | 11 (3) | 7 (2) |
| Mucinous | 7 (1) | 3 (1) | 4 (1) |
| Other | 40 (6) | 22 (6) | 18 (5) |
| Opted to receive bevacizumab | |||
| Yes | 580 (84) | 291 (84) | 289 (84) |
| No | 112 (16) | 55 (16) | 57 (16) |
| Opted to receive neoadjuvant therapy | |||
| Yes | 88 (13) | 44 (13) | 44 (13) |
| No | 604 (87) | 302 (87) | 302 (87) |
*
Percentages may not sum to 100 because of rounding. There were no significant differences between the groups in the characteristics at baseline. For details on race, performance-status scores, and histologic grade, see Table S1 in the Supplementary Appendix.
†
The size of residual disease was not assessed in patients who underwent neoadjuvant therapy.